$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
028-123456789
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
medicaldrugs
medicaldrugs
Detailed description of Zongatinib (Zongatinib) indications, main disease types and clinical application guidelines
2026-02-01 22:25:32
Check Details
A complete explanation of the applicable populations and clinical applications of vosoritide
2026-02-01 22:25:32
Check Details
The leukemia targeted drug Gilteritinib has been launched in China, and its clinical efficacy and medication methods are explained in detail
2026-02-01 22:25:32
Check Details
Pomalidomide/octuzumab/zanubrutinib/venetoclax quadruple therapy is effective in high-risk MCL
2026-02-01 22:25:32
Check Details
What is the approximate price of Lapatinib in India and is it worth buying?
2026-02-01 22:25:32
Check Details
What exactly is filgotinib and what is it used for?
2026-02-01 22:25:32
Check Details
What are the effects of selumetinib/coceyu on children?
2026-02-01 22:25:32
Check Details
Pharmacological effects and mechanisms of lorlatinib/lorlatinib (borina)
2026-02-01 22:25:32
Check Details
Differences between the two dosage forms of Cabozantinib
2026-02-01 22:25:32
Check Details
What are the targeted therapeutic genes of bosutinib/bosutinib?
2026-02-01 22:25:32
Check Details
What is the medical insurance reimbursement process for Nintedanib and what should you prepare?
2026-02-01 22:25:32
Check Details
Is Upatinib/Refu considered a targeted drug? What are its clinical applications?
2026-02-01 22:25:32
Check Details
1
2
...
2416
2417
2418
2419
2420
2421
2422
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
User Agreement
2
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
3
What is the most important information I should know about WELIREG?
4
How to take and store WELIREG
5
How to take TRUSELTIQ correctly
6
How to deal with LONSURF side effects (1)
7
How to deal with LONSURF side effects (2)
8
Cabozantinib (Cabometyx)-new indication approved
9
What should I pay attention to when using atezolizumab/Tecentriq?
10
Darzalex Faspro, Kyprolis and dexamethasone "three swords combined" to treat multiple myeloma
11
Rituximab combined with chemotherapy approved in the United States for pediatric patients with specific malignant tumors
12
Lenvatinib and pembrolizumab trial results in unresectable hepatocellular carcinoma